ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.593,31
1,06%
S&P 500
6.084,19
0,82%
US Dollar vs BRL
5,9549
-0,02%
Bitcoin
100.727,40
-0,46%
Brent Oil
73,565
0,16%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) Notícias

NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLTX
DataHoraFonteTítuloCódigoCompanhia
09/08/202417:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
09/08/202408:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
17/06/202415:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202415:33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202417:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
07/03/202418:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
20/02/202418:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202420:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202418:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
18/01/202420:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
21/12/202318:05Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NLTXNeoleukin Therapeutics Inc
14/12/202321:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
06/12/202318:24Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NLTXNeoleukin Therapeutics Inc
08/11/202316:34Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
22/09/202309:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
18/07/202307:30GlobeNewswire Inc.Neurogene and Neoleukin Announce Definitive Merger AgreementNASDAQ:NLTXNeoleukin Therapeutics Inc
12/06/202317:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/05/202317:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202315:01Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202313:48Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202313:44Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
14/04/202317:52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
21/03/202307:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NLTXNeoleukin Therapeutics Inc
10/03/202310:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/03/202319:00GlobeNewswire Inc.Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202318:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLTXNeoleukin Therapeutics Inc
03/02/202313:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLTXNeoleukin Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NLTX

Seu Histórico Recente

BOV
TELB4
TELEBRAS PN
BOV
ATOM3
ATOMPAR ON
BOV
IBOV
Índice Bovespa
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
OIBR3
OI ON
BOV
TPIS3
TRIUNFO PART ON
BOV
MELK3
Melnick Desenvolvimento ... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados